Coronavirus disease 2019 (COVID‐19) has become a pandemic disease globally. Although COVID-19 directly invades lungs, it also involves the nervous system. Therefore, patients with nervous system involvement as the presenting symptoms in the early stage of infection may easily be misdiagnosed and their treatment delayed. They become silent contagious sources or ‘virus spreaders’. In order to help neurologists to better understand the occurrence, development and prognosis, we have developed this consensus of prevention and management of COVID‐19. It can also assist other healthcare providers to be familiar with and recognise COVID-19 in their evaluation of patients in the clinic and hospital environment.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
Collaborators Kangning Chen (email@example.com, Department of Neurology, The Southwest Hospital, the First Affiliated Hospital of Third Military Medical University, Chongqing, China), Liying Cui (firstname.lastname@example.org, Department of Neurology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China), Qiang Dong (email@example.com, Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China), Chuanqiang Pu (firstname.lastname@example.org, Department of Neurology, The General Hospital of Chinese People’s Liberation Army, Beijing, China), Furong Wang (email@example.com, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China), Yongjun Wang (firstname.lastname@example.org, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China), Bo Xiao (email@example.com, Department of Neurology, Xiangya Hospital, Central South University, Changsha, China), Peng Xie (firstname.lastname@example.org, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China), Anding Xu (email@example.com, Department of Neurology and Stroke Center, the First Affiliated Hospital, Jinan University, Guangzhou, China), Yun Xu (firstname.lastname@example.org, Department of Neurology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China), Qingwu Yang (email@example.com, Department of Neurology, Xinqiao Hospital, Third Military Medical University, Chongqing, China), Jinsheng Zeng (firstname.lastname@example.org, Department of Neurology and Stroke Center, the First Affiliated Hospital of Sun Yat-Sen University, Guangdong, China), Junjian Zhang (email@example.com, Department of Neurology, Zhongnan Hospital of Wuhan University, Wuhan, China), Zhaohui Zhang (firstname.lastname@example.org, Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China) and Gang Zhao (email@example.com, Department of Neurology, Xijing Hospital, The 4th Military Medical University, Xi’an, China).
Contributors BH and LW designed the framework and also participated in revision. HJ drafted the sections of key points for the treatment of coronavirus disease 2019 (COVID-19) and revised the whole manuscript. CH drafted the sections of precautions for neurologists. SC drafted the sections of clinical characteristics of COVID-19. YZ drafted the sections of introduction and the overview of the novel coronavirus. YW drafted the sections of possible causes of neurological symptoms and precautions in treatment. LM, YL, QH, ML, YS and DW revised the whole manuscript.
Funding This work was supported by the National Key Research and Development Program of China (No. 2018YFC1312200 to BH), the National Natural Science Foundation of China (No. 81820108010 to BH, No. 81974182 to LM and No. 81671147 to HJ) and major refractory diseases pilot project of clinical collaboration with Chinese and Western Medicine (SATCM-20180339).
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.